Capital market company KICVentures Group has completed the acquisition of NanoFuse Biologics.
The acquisition was entered in March 2018 and structured as a five-year deal with milestones.
KICVentures Group accelerated milestone payments to complete the acquisition within three years. The final milestone payment was made in September.
"With an accelerated closure of this acquisition, we are positioned to independently negotiate strategic partnerships and prepare the company for an IPO in three years," Aditya Humad, CFO of KICVentures Group, said in a Dec. 23 news release.
NanoFuse Biologics is the developer of the only FDA-cleared bioactive glass and demineralized bone matrix combined device.